Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities

Author(s): Howard S. Roth, Paul J. Hergenrother

Journal Name: Current Medicinal Chemistry

Volume 23 , Issue 3 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


PAC-1 induces the activation of procaspase-3 in vitro and in cell culture by chelation of inhibitory labile zinc ions via its ortho-hydroxy-N-acylhydrazone moiety. First reported in 2006, PAC-1 has shown promise in cell culture and animal models of cancer, and a Phase I clinical trial in cancer patients began in March 2015 (NCT02355535). Because of the considerable interest in this compound and a well-defined structure-activity relationship, over 1000 PAC-1 derivatives have been synthesized in an effort to vary pharmacological properties such as potency and pharmacokinetics. This article provides a comprehensive examination of all PAC-1 derivatives reported to date. A survey of PAC-1 derivative libraries is provided, with an indepth discussion of four derivatives on which extensive studies have been performed.

Keywords: PAC-1, procaspase-3, zinc, apoptosis, cancer, library.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 22 January, 2016
Page: [201 - 241]
Pages: 41
DOI: 10.2174/0929867323666151127201829
Price: $65

Article Metrics

PDF: 69
HTML: 10
PRC: 1